facial infiltrating lipomatosis fil also referred congenital infiltrating lipomatosis face facial infused lipomatosis ultrarare craniofacial overgrowth condition caused genetic mutation condition part related overgrowth spectrum disease congenital nonhereditary first described slavin colleagues disease mutation causes overgrowth half face hemifacial affects soft hard tissue facial skeleton condition noticeable birth asymmetrical cheeks one cheek prominently larger congenital hemifacial enlargement mature lipocytes invade adjacent tissue phenotypic features include softtissue skeletal hypertrophy regional macrodontia manifestations variable ranging mild severe overgrowth typically present birth common features features one affected side face patients facial infiltrating lipomatosis symptoms mutations gene identified cause facial infiltrating mutation de novo mosaic meaning new inherited occurring every cell one dna nucleotides altered causing change amino acid put protein referred missense mutation pros gives overactivity gainoffunction gene part pathway pathway crucial cell growth survival angiogenesis proliferationcitation needed cure filpros management usually consists multiple debulking surgeries andor drug treatment due infiltrating fat important facial structures complete excision overgrowth often impossible high risk regrowth current drug treatment options either mtor inhibitor pan akt inhibitor inhibitor mtor inhibitor offlabel use use aktinhibitor currently clinical mosaic inhibitor available compassionate use one eligible httpsenwikipediaorgwikifacialinfiltratinglipomatosis